SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for THOMSON REUTERS (TRI) — Jun 15, 2012

THOMSON REUTERS CORP /CAN/ (TRI, TMSOF) (CIK 0001075124)
Date: June 15, 2012 · CIK: 0001075124 · Accession: 0000000000-12-031324

AI Filing Summary & Sentiment

File numbers found in text: 001-31349

Date
May 30, 2012
Author
/s/ Lyn Shenk
Form
UPLOAD
Company
THOMSON REUTERS CORP /CAN/ (TRI, TMSOF) (CIK 0001075124)

Letter

May 30, 2012 Via E -mail Stephane Bello Chief Financial Officer Thomson Reuters Corporation 3 Times Square New York, NY 10036

Re: Thomson Reuters Corporation Form 40-F for Fiscal Year Ended December 31 , 2011 Filed March 19, 201 2 File No. 001-31349

Dear Mr. Bellow :

We have reviewed your filing and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please r espond to this letter within 10 business days by confirming that you will revise your document in future filings and providing any requested information . If you do not believe our comment apply to your facts and circumstances, please tell us why in your response.

After reviewing any amendment to your filing and the information you provide in response to these comment, we may have additional comments.

Form 40-F for Fiscal Year Ended December 31, 2012

Other Businesses, page 11

1. We note disclosure in exhibits 99.1 and .2 of the Form 6 -K filed on May 3, 2012 reporting your interim results for the period ended March 31, 2012 that you entered into a definitive agreement to sell the Health care business for $1.25 billion and that you expect a significant gain on the transaction. In this filing you include the Healthcare business in “other businesses,” which is an aggregation of businesses reported within continuing operations that have been or are expected to be exited through sale or closure that d o not qualify for discontinued operations classification . We also note that the Healthcare business appears to have been a component of the “Healthcare & Science” reportable segment previously pr esented. Please explain to us your basis for not classifying the healthcare business as a discontinued operation pursuant to paragraphs 31 and 32(a) of International Financial Reporting Standard 5 when the business appears to be a component that represent s a separate major line of business.

Stephane Bello Thomson Reuters Corporation May 30, 2012 Page 2

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable Exchange Act rules require. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

In responding to our comments, p lease provide a written statement from the company acknowledging that:

the company is responsible for the adequacy and accuracy of the disclosure in the filing;

staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and

the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

You may c ontact T heresa Messinese at 202 -551-3307 or Doug Jones at 202 - 551-3309 if you have questions regarding the comment s and related matters . Please contact me at 202 -551- 3380 with any other questions.

Sincerely,
/s/ Lyn Shenk

Show Raw Text
May 30, 2012

Via E -mail
Stephane Bello
Chief Financial Officer
Thomson Reuters Corporation
3 Times Square
New York, NY  10036

Re: Thomson Reuters Corporation
 Form 40-F for Fiscal Year Ended December 31 , 2011
Filed March  19, 201 2
File No. 001-31349

Dear Mr. Bellow :

We have reviewed your filing  and have the following comment.  In our comment, we
may ask you to provide us with information so we may better understand your disclosure.

Please r espond to this letter within 10  business days by confirming that you will revise
your document in future filings  and providing any requested information .  If you do not believe
our comment  apply  to your facts and circumstances, please tell us why in your response.

After reviewing any amendment to your filing and the information you provide in
response to these comment, we may have additional comments.

Form 40-F for Fiscal Year  Ended December  31, 2012

Other Businesses, page 11

1. We note disclosure in exhibits 99.1 and .2 of the Form 6 -K filed on May 3, 2012
reporting your interim results for the period ended March 31, 2012 that you entered into a
definitive agreement to sell the Health care business for $1.25 billion and that you expect
a significant gain on the transaction.  In this filing you include the Healthcare business in
“other businesses,” which is an aggregation of businesses reported within continuing
operations that have been  or are expected to be exited through sale or closure that d o not
qualify for discontinued operations classification .  We also note that the Healthcare
business appears to have been a component of the “Healthcare & Science” reportable
segment previously pr esented.  Please explain to us your basis for not classifying the
healthcare business as a discontinued operation pursuant to paragraphs 31 and 32(a) of
International Financial Reporting Standard 5 when the business appears to be a
component that represent s a separate major line of business.

Stephane Bello
Thomson  Reuters Corporation
May 30, 2012
Page 2

We urge all persons who are responsible for the accuracy and adequacy of the disclosure
in the filing to be certain that the filing includes the information the Securities Exchange Act of
1934 and all applicable  Exchange Act rules require.   Since the company and its management are
in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy
and adequacy of the disclosures they have made.

 In responding to our comments, p lease provide  a written statement from the company
acknowledging that:

 the company is responsible for the adequacy and accuracy of the disclosure in the filing;

 staff comments or changes to disclosure in response to staff comments do not foreclose
the Commission from taking any action with respect to the filing; and

 the company may not assert staff comments as a defense in any proceeding initiated by
the Commission or any person under the federal securities laws of the United States.

You may c ontact T heresa Messinese at 202 -551-3307 or Doug Jones at 202 - 551-3309 if
you have questions regarding the comment s and related  matters .  Please contact me at 202 -551-
3380 with any other questions.

Sincerely,

 /s/ Lyn Shenk

 Lyn Shenk
Branch Chief